http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-0112920-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9d12b35c0dd9adfb167b3b4f383afe93 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-14 |
| filingDate | 2001-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2003-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-0112920-A |
| titleOfInvention | Variolin B derivatives |
| abstract | "VARIOLIN B DERIVATIVES". The invention provides anti-tumor compounds of formula (I), wherein R2 is an aromatic substituent; R 2 is hydrogen or a substituent when the dotted line is absent, or R 2 is missing when the dotted line represents a bond to produce a double bond between the nitrogen carrying R 2 and the carbon carrying R 2. ^ 3 ^; R3 is a group oxo = O when the dotted line is absent or is a substituent when the dotted line represents a bond to produce a double bond between nitrogen carrying R2 and carbon carrying R3; R4 is hydrogen or a substituent; and pharmaceutically acceptable salts thereof. |
| priorityDate | 2000-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 23.